Aperio Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $3.35M | Buy |
34,936
+348
| +1% | +$33.4K | 0.01% | 1006 |
|
|
2020
Q3 | $3.33M | Sell |
34,588
-716
| -2% | -$68.9K | 0.01% | 891 |
|
|
2020
Q2 | $4.31M | Buy |
35,304
+1,285
| +4% | +$157K | 0.02% | 777 |
|
|
2020
Q1 | $2.95M | Sell |
34,019
-2,228
| -6% | -$193K | 0.01% | 853 |
|
|
2019
Q4 | $3.9M | Buy |
36,247
+2,557
| +8% | +$275K | 0.01% | 835 |
|
|
2019
Q3 | $3.04M | Sell |
33,690
-52
| -0.2% | -$4.69K | 0.01% | 884 |
|
|
2019
Q2 | $2.85M | Buy |
33,742
+5,642
| +20% | +$476K | 0.01% | 913 |
|
|
2019
Q1 | $2.48M | Buy |
28,100
+244
| +0.9% | +$21.5K | 0.01% | 954 |
|
|
2018
Q4 | $1.99M | Sell |
27,856
-2,715
| -9% | -$194K | 0.01% | 990 |
|
|
2018
Q3 | $3.76M | Buy |
30,571
+1,866
| +7% | +$229K | 0.02% | 781 |
|
|
2018
Q2 | $2.82M | Buy |
28,705
+1,658
| +6% | +$163K | 0.01% | 865 |
|
|
2018
Q1 | $2.24M | Buy |
27,047
+2,080
| +8% | +$172K | 0.01% | 942 |
|
|
2017
Q4 | $1.94M | Buy |
24,967
+3,055
| +14% | +$237K | 0.01% | 994 |
|
|
2017
Q3 | $1.34M | Sell |
21,912
-412
| -2% | -$25.3K | 0.01% | 1119 |
|
|
2017
Q2 | $1.03M | Buy |
22,324
+789
| +4% | +$36.3K | 0.01% | 1227 |
|
|
2017
Q1 | $932K | Sell |
21,535
-2,479
| -10% | -$107K | 0.01% | 1204 |
|
|
2016
Q4 | $929K | Buy |
24,014
+5,200
| +28% | +$201K | 0.01% | 1167 |
|
|
2016
Q3 | $953K | Buy |
18,814
+7,294
| +63% | +$369K | 0.01% | 1126 |
|
|
2016
Q2 | $523K | Buy |
11,520
+2,114
| +22% | +$96K | ﹤0.01% | 1359 |
|
|
2016
Q1 | $372K | Buy |
9,406
+1,761
| +23% | +$69.6K | ﹤0.01% | 1522 |
|
|
2015
Q4 | $432K | Buy |
7,645
+901
| +13% | +$50.9K | ﹤0.01% | 1416 |
|
|
2015
Q3 | $268K | Buy |
6,744
+760
| +13% | +$30.2K | ﹤0.01% | 1620 |
|
|
2015
Q2 | $286K | Buy |
5,984
+654
| +12% | +$31.3K | ﹤0.01% | 1667 |
|
|
2015
Q1 | $212K | Buy |
+5,330
| New | +$212K | ﹤0.01% | 1798 |
|